Navigation Links
Human Genome Sciences and Xencor Announce Antibody Collaboration
Date:2/7/2008

Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, Inc., ... Inc. (NASDAQ: SQNM ), the leading ... for next generation noninvasive prenatal tests (NIPT). Through ... technology, called Mantis™, to advance analysis of clinically-relevant ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... PRINCETON, N.J., May 26 Medarex, Inc. (Nasdaq: ... live webcast at 4:00 p.m. Eastern Time on Tuesday, June ... Product Development at Medarex will provide an update and recent ... archive can be accessed through the Investor Relations section of ...
... announces it is developing a novel technology that can ... but can also be used in a wide range ... art, currency, electronic components, high value added ingredients, to ... go to: http://www.prnewswire.com/mnr/trutag/38547/ (Photo: ...
... 26 Vaxart, Inc., a biotechnology company focused on ... company has created a candidate vaccine for H1N1 influenza ... for immune responses in animals, just 25 days after ... the research-grade H1N1 vaccine to its successful avian flu ...
Cached Biology Technology:Medarex to Host Clinical Program Update Conference Call on Tuesday, June 2, 2009 2Photos: Breakthrough Technology Enables Edible TruTag(TM) to Prevent Counterfeit Medicine 2Photos: Breakthrough Technology Enables Edible TruTag(TM) to Prevent Counterfeit Medicine 3Vaxart Begins Animal Testing of H1N1 Flu Vaccine Candidate 2
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used for the ... facial feature of a person such as nose, jaw ...
(Date:12/11/2014)...  That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... One of the few studies of its type has found ... Oregon university were "food insecure" at some point during the ... emotional health and other issues. Contrary to concerns about ... weight gain, another reality is that many students are not ...
... The sponges of the future will do more than clean ... to soak up a drug and deliver it directly to a ... store unwanted gases. These technologies are what University at ... when he led the design of a new material called UBMOF-1. ...
... to kill insects and fungi also kill honeybee larvae within ... researchers. The team also found that N-methyl-2-pyrrolidone (NMP) -- an ... -- is highly toxic to honeybee larvae. "We found ... kill bee larvae," said Jim Frazier, professor of entomology, Penn ...
Cached Biology News:Study identifies high level of 'food insecurity' among college students 2Study identifies high level of 'food insecurity' among college students 3Swiss cheese crystal, or high-tech sponge? 2Common crop pesticides kill honeybee larvae in the hive 2Common crop pesticides kill honeybee larvae in the hive 3
... Agencourts cDNA sequencing and finishing ... needs. Agencourt can perform large-scale 5' ... and finishing. Our considerable experience with ... programs make Agencourt an ideal cDNA ...
Shotgun library construction and high-throughput DNA sequencing of microbial genomes, BACs, adenoviruses, phosmids and cosmids. LIMS tracking utilizing Geospiza's Finch system....
... human XAB2 (amino terminus) XAB2 (XPA-binding ... interaction with XPA. Immunoprecipitation experiments have also ... with the transcription-coupled repair-specific proteins CSA and ... II. Microinjection experiments with XAB2 antibodies resulted ...
...
Biology Products: